Differential diagnosis and management of Behçet syndrome

Nat Rev Rheumatol. 2013 Feb;9(2):79-89. doi: 10.1038/nrrheum.2012.156. Epub 2012 Sep 25.

Abstract

Behçet syndrome (also known as Behçet disease) is a rare condition that is associated with considerable morbidity. Cases of Behçet syndrome have been reported worldwide, but the highest prevalence occurs in countries that border the ancient Silk Route, such as Turkey and Iran. Although oral ulceration, genital ulceration and eye disease are the classic triad of manifestations, the cardiovascular, gastrointestinal, musculoskeletal and central nervous systems can also be affected. The syndrome is chronic and relapsing with some patients having benign episodes whereas others have more serious complications, including blindness or the rupture of a pulmonary arterial aneurysm. Diagnosing Behçet syndrome, particularly outside of endemic regions, often incurs a considerable delay owing to the rarity of this condition. Furthermore, a paucity exists of data from randomized controlled trials on the optimal therapeutic approaches to use in patients, as well as a lack of informative laboratory surrogate markers to monitor disease progression. This Review discusses the issues surrounding the diagnosis and differential diagnosis of Behçet syndrome and presents the current approaches to managing patients with this complex group of disorders.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Azathioprine / therapeutic use
  • Behcet Syndrome / diagnosis*
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / epidemiology
  • Diagnosis, Differential
  • Disease Management*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Prevalence
  • Steroids / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Immunosuppressive Agents
  • Steroids
  • Tumor Necrosis Factor-alpha
  • Azathioprine